rss
Br J Ophthalmol 2009;93:1033-1036 doi:10.1136/bjo.2008.148874
  • Original Article
  • Clinical Science

Short-term response of macular oedema to intravitreal bevacizumab

  1. D E Welch1,
  2. H Elmariah1,
  3. M C Peden1,
  4. S G Adams1,
  5. R Ratnakaram1,
  6. S Kaushal2
  1. 1
    Department of Ophthalmology, University of Florida, Gainesville, Florida, USA
  2. 2
    Department of Ophthalmology, University of Massachusetts School of Medicine, Worcester, Massachusetts, USA
  1. Correspondence to Dr S Kaushal, Department of Ophthalmology, University of Massachusetts School of Medicine, 55 Lake Avenue North, Worcester, MA 01655, USA; shalesh.kaushal{at}umassmemorial.org
  • Accepted 13 February 2009
  • Published Online First 28 April 2009

Abstract

Background/aims: Bevacizumab has been shown to be an effective treatment of macular oedema. This study assesses the response of macular oedema to bevacizumab with specific focus on the first 24 h postinjection.

Methods: Subjects with diabetic macular oedema (DMO) or exudative age-related macular degeneration (ARMD) received intravitreal bevacizumab injections. Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity and OCT macular thickness measurements were obtained at baseline, 1, 3, 6, 24 and 48 h, 1 week and 1 month postinjection.

Results: The average baseline OCT was 452.91 µm (SD 182.96, range 249.00 to 784.00). After injection, there was a statistically significant decrease in OCT thickness within 2 h with a plateau phase out to 24 h, followed by a significant drop between 24 and 48 h, and a return towards baseline between 1 week and 1 month. Average changes in ETDRS visual acuity were not statistically significant, though many patients experienced a positive outcome.

Conclusion: While there is an immediate pressure-related effect, it appears that the anti-VEGF effects of bevacizumab require approximately 24 h to become active and persist for 2–3 weeks. These results suggest that injections at 2–3-week intervals might provide improved clinical outcomes, compared with the currently typical 4–6-week interval of injections.

Footnotes

  • Funding This study was funded by the Charlie Mac Overstreet Laboratory for Retinal Diseases and Research to Prevent Blindness.

  • Competing interests None.

  • Ethics approval Ethics approval was provided by the Institutional Review Board of the University of Florida at the Gainesville Health Science Center in Gainesville, Florida.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2008.148874v1
    2. 93/8/1033 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.